These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 15116956

  • 1. Screening of endocrine disrupting chemicals using a surface plasmon resonance sensor.
    Asano K, Ono A, Hashimoto S, Inoue T, Kanno J.
    Anal Sci; 2004 Apr; 20(4):611-6. PubMed ID: 15116956
    [Abstract] [Full Text] [Related]

  • 2. Characterization of protein--DNA interactions using surface plasmon resonance spectroscopy with various assay schemes.
    Teh HF, Peh WY, Su X, Thomsen JS.
    Biochemistry; 2007 Feb 27; 46(8):2127-35. PubMed ID: 17266332
    [Abstract] [Full Text] [Related]

  • 3. Impact of biochemical design on estrogen receptor/estrogen response element interaction by surface plasmon resonance technology.
    Habauzit D, Bayle S, Benimelis D, Chopineau J, Roig B.
    Arch Biochem Biophys; 2014 Jan 01; 541():61-6. PubMed ID: 24280273
    [Abstract] [Full Text] [Related]

  • 4. Effects of environmental estrogenic chemicals on AP1 mediated transcription with estrogen receptors alpha and beta.
    Fujimoto N, Kitamura S.
    J Steroid Biochem Mol Biol; 2004 Jan 01; 88(1):53-9. PubMed ID: 15026083
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of endocrine disruptor screening tests in detecting anti-estrogenic effects downstream of receptor-ligand interactions.
    Takeyoshi M, Yamasaki K, Sawaki M, Nakai M, Noda S, Takatsuki M.
    Toxicol Lett; 2002 Jan 25; 126(2):91-8. PubMed ID: 11751013
    [Abstract] [Full Text] [Related]

  • 6. Critical parameters in surface plasmon resonance biosensor development: The interaction between estrogen receptor and estrogen response element as model.
    Bayle S, Benimelis D, Chopineau J, Roig B, Habauzit D.
    Biochimie; 2020 Jan 25; 171-172():12-20. PubMed ID: 32017967
    [Abstract] [Full Text] [Related]

  • 7. Screening of endocrine disrupting chemicals with MELN cells, an ER-transactivation assay combined with cytotoxicity assessment.
    Berckmans P, Leppens H, Vangenechten C, Witters H.
    Toxicol In Vitro; 2007 Oct 25; 21(7):1262-7. PubMed ID: 17572059
    [Abstract] [Full Text] [Related]

  • 8. A new bisphenol A derivative for estrogen receptor binding studies with surface plasmon resonance.
    Wong WL, Chow CF.
    Environ Toxicol Chem; 2015 Jun 25; 34(6):1390-6. PubMed ID: 25690832
    [Abstract] [Full Text] [Related]

  • 9. Novel Estrogen Receptor Dimerization BRET-Based Biosensors for Screening Estrogenic Endocrine-Disrupting Chemicals.
    Choi G, Kang H, Suh JS, Lee H, Han K, Yoo G, Jo H, Shin YM, Kim TJ, Youn B.
    Biomater Res; 2024 Jun 25; 28():0010. PubMed ID: 38464469
    [Abstract] [Full Text] [Related]

  • 10. The assessment of estrogenic or anti-estrogenic activity of chemicals by the human stably transfected estrogen sensitive MELN cell line: results of test performance and transferability.
    Witters H, Freyberger A, Smits K, Vangenechten C, Lofink W, Weimer M, Bremer S, Ahr PH, Berckmans P.
    Reprod Toxicol; 2010 Aug 25; 30(1):60-72. PubMed ID: 20362049
    [Abstract] [Full Text] [Related]

  • 11. New screening methods for chemicals with hormonal activities using interaction of nuclear hormone receptor with coactivator.
    Nishikawa J, Saito K, Goto J, Dakeyama F, Matsuo M, Nishihara T.
    Toxicol Appl Pharmacol; 1999 Jan 01; 154(1):76-83. PubMed ID: 9882594
    [Abstract] [Full Text] [Related]

  • 12. Label-free sensing and atomic force spectroscopy for the characterization of protein-DNA and protein-protein interactions: application to estrogen receptors.
    Berthier A, Elie-Caille C, Lesniewska E, Delage-Mourroux R, Boireau W.
    J Mol Recognit; 2011 Jan 01; 24(3):429-35. PubMed ID: 21504020
    [Abstract] [Full Text] [Related]

  • 13. Relationship between the results of in vitro receptor binding assay to human estrogen receptor alpha and in vivo uterotrophic assay: comparative study with 65 selected chemicals.
    Akahori Y, Nakai M, Yamasaki K, Takatsuki M, Shimohigashi Y, Ohtaki M.
    Toxicol In Vitro; 2008 Feb 01; 22(1):225-31. PubMed ID: 17904329
    [Abstract] [Full Text] [Related]

  • 14. The transcriptional regulation of an antimicrobial peptide hepcidin1 in Oryzias melastigma upon EE2 exposure involved in a new pathway with a novel transcriptional regulatory element HepERE.
    Zhang M, Zhang MF, Chen FY, Cui Q, Yang BZ, Liu Y, Peng H, Wang KJ.
    Fish Shellfish Immunol; 2018 Nov 01; 82():421-431. PubMed ID: 30125706
    [Abstract] [Full Text] [Related]

  • 15. Development of QSAR models for predicting the binding affinity of endocrine disrupting chemicals to eight fish estrogen receptor.
    He J, Peng T, Yang X, Liu H.
    Ecotoxicol Environ Saf; 2018 Feb 01; 148():211-219. PubMed ID: 29055205
    [Abstract] [Full Text] [Related]

  • 16. Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element.
    Kostelac D, Rechkemmer G, Briviba K.
    J Agric Food Chem; 2003 Dec 17; 51(26):7632-5. PubMed ID: 14664520
    [Abstract] [Full Text] [Related]

  • 17. Surface plasmon resonance-based immunoassay for 17beta-estradiol and its application to the measurement of estrogen receptor-binding activity.
    Miyashita M, Shimada T, Miyagawa H, Akamatsu M.
    Anal Bioanal Chem; 2005 Feb 17; 381(3):667-73. PubMed ID: 15662513
    [Abstract] [Full Text] [Related]

  • 18. A screening method for estrogens using an array-type DNA glass slide.
    Kim SB, Ozawa T, Umezawa Y.
    Anal Sci; 2003 Apr 17; 19(4):499-504. PubMed ID: 12725382
    [Abstract] [Full Text] [Related]

  • 19. AroER tri-screen™ is a novel functional assay to estimate both estrogenic and estrogen precursor activity of chemicals or biological specimens.
    Kanaya N, Nguyen DM, Lu H, Wang YZ, Hsin LY, Petreas M, Nelson D, Guo W, Reynolds P, Synold T, Chen S.
    Breast Cancer Res Treat; 2015 Jun 17; 151(2):335-45. PubMed ID: 25962693
    [Abstract] [Full Text] [Related]

  • 20. An integrated "4-phase" approach for setting endocrine disruption screening priorities--phase I and II predictions of estrogen receptor binding affinity.
    Shi L, Tong W, Fang H, Xie Q, Hong H, Perkins R, Wu J, Tu M, Blair RM, Branham WS, Waller C, Walker J, Sheehan DM.
    SAR QSAR Environ Res; 2002 Mar 17; 13(1):69-88. PubMed ID: 12074393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.